BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $353.00 Consensus Target Price from Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $357.3333.

Several research analysts recently issued reports on ONC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Barclays assumed coverage on BeOne Medicines in a research report on Thursday, September 18th. They set an “overweight” rating and a $385.00 price target on the stock. Morgan Stanley lifted their price objective on BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Finally, JPMorgan Chase & Co. raised their target price on shares of BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th.

BeOne Medicines Price Performance

BeOne Medicines stock opened at $377.47 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. The stock has a market cap of $41.39 billion, a price-to-earnings ratio of 740.14 and a beta of 0.31. The firm has a 50-day moving average of $328.43 and a two-hundred day moving average of $290.11. BeOne Medicines has a 1 year low of $170.99 and a 1 year high of $379.33.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $337.00, for a total transaction of $898,105.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Titus B. Ball sold 122 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $326.76, for a total value of $39,864.72. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,267 shares of company stock valued at $18,740,356 over the last quarter. 6.62% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA purchased a new stake in BeOne Medicines in the second quarter valued at about $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in BeOne Medicines in the 2nd quarter worth approximately $244,603,000. Marshall Wace LLP purchased a new stake in BeOne Medicines during the 2nd quarter worth approximately $113,190,000. Baird Financial Group Inc. acquired a new position in BeOne Medicines during the 2nd quarter valued at approximately $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of BeOne Medicines in the second quarter worth $73,347,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.